Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485953 · ClinicalTrials.gov registry record · Phase 4
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
A Phase 4 study, sponsored by Susan L. Greenspan.
- Completed
- Registry status
- Phase 4
- Development phase
- 109
- Enrollment target
NCT00485953: Completed Phase 4 study, sponsored by Susan L. Greenspan.
NCT00485953 is a Phase 4 study that has completed, run by Susan L. Greenspan. The registered enrollment target is 109 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485953, a Phase 4 study, has completed, sponsored by Susan L. Greenspan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 109 participants
- Enrollment target
Study Summary
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1) prevent bone loss at clinically relevant sites, such as the spine and hip and (2) decrease bone turnover.
Primary Outcome
BMD is the bone mineral density of the lumbar spine measured using the dual-energy x-ray absorptometry (DXA) scan.
Interventions
- DRUG risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
What the finished NCT00485953 record still lists
NCT00485953 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which risedronate is the first listed.
NCT00485953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00485953 about?
NCT00485953 is a clinical study titled "Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy". Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1) prevent bone loss at clinical...
What is the current status of trial NCT00485953?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2007-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00485953?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00485953?
This trial is sponsored by Susan L. Greenspan, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00485953's enrollment target sits among peer trials
109 737th of 2000 higher than 1,261 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia